Definium Therapeutics, Inc. · NASDAQ:DFTX
Definium Therapeutics — Mind Medicine (MindMed) — Investor Presentation (January 2026)
29 slides from Definium Therapeutics's investor presentation, Jan 12, 2026
Slide 1: Corporate Presentation January 2026
Corporate Presentation January 2026
Slide 2: Disclaimer and Cautionary Note Regarding Forward-Looking Statements
This presentation (the “Presentation”) has been prepared by Definium Therapeutics, Inc. (“Definium”, the “Company”, “we”, “our” or “us") solely for informational purposes. This Presentation does not constitute an offering of, or a solicitation of an offer to purchase, securities of Definium and unde
Slide 3: Late-stage pipeline and investment highlights
Late-stage pipeline DT120 ODT: lead clinical program in four Phase 3 studies1 Experienced management team Proven track record in developing and commercializing novel CNS therapies Three Phase 3 readouts anticipated in 2026 driving potential billion-dollar commercial opportunities in GAD and MDD Incl
Slide 4: Anxiety & Depressive Disorders Represent a Massive and Growing Unmet Need
Confidential – For internal use only Anxiety & Depressive Disorders Represent a Massive and Growing Unmet Need 56%3 GAD & MDD Prevalence >50 million1 GAD & MDD Annual Growth Rate 5%+2 Psychiatry Needs Better Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Fi
Slide 5: Advancing Our Pipeline with Broad Therapeutic Potential
Corporate Presentation | January 2026 Advancing Our Pipeline with Broad Therapeutic Potential PRODUCT CANDIDATE INDICATION PRECLINICAL PHASE 1 PHASE 2 PIVOTAL / PHASE 3 REGISTRATION DT120 ODT Lysergide tartrate1 Generalized Anxiety Disorder (GAD)3 Major Depressive Disorder (MDD)3 Additional Indicati
Slide 6: Program Overview: DT120 ODT Lysergide tartrate
Program Overview DT120 ODT Lysergide tartrate 01
Slide 7: DT120 Phase 2b Efficacy and Durability Demonstrates Potential Best-In-Class Profile
Corporate Presentation | January 2026 DT120 Phase 2b Efficacy and Durability Demonstrates Potential Best-In-Class Profile1,3 Standardized effect size more than double the standard of care1,2,3 Comparative Effect Sizes in GAD Rapid and durable response after single administration3 Rapid Response & Re
Slide 8: Scientific Rigor in Phase 2b Provides Confidence for Phase 3 Program
Scientific Rigor in Phase 2b Provides Confidence for Phase 3 Program Corporate Presentation | January 2026 Statistically significant dose response in Phase 2b Model supports 100 µg as optimal dose Results not explainable by “functional unblinding” supporting robustness of drug effect Study MMED008 i
Slide 9: Primary Outcome: HAM-A Change from Baseline
Primary Outcome: HAM-A Change from Baseline Corporate Presentation | January 2026 Source: Study MMED008 internal study documents and calculations. Full analysis set population. Based on 100 µg dose group. Based on observed MADRS score at each timepoint. Primary endpoint of the study was change in Ha
Slide 10: DT120 Demonstrated Profound Changes in GAD Severity
Remission (≤7) Symptoms are absent, insignificant, or clearly due to causes other than anxiety Mild (8-14) Symptoms are infrequent, with no impairment and no more than mild distress Moderate (15-23) Symptoms are more frequent, with moderate distress or limited interference with usual activities Very
Slide 11: DT120 was Well-Tolerated with Adverse Events Mostly Limited to Dosing Day
Corporate Presentation | January 2026 DT120 was Well-Tolerated with Adverse Events Mostly Limited to Dosing Day1 Source: Study MMED008 internal study documents and calculations. Safety population. One serious adverse event (SAE) was observed in the 50 µg dose group: panic attack on study day 98 that
Slide 12: Rigorous Development Approach Addresses Key Regulatory Considerations
Rigorous Development Approach Addresses Key Regulatory Considerations Corporate Presentation | January 2026 Complementary clinical study designs intended to generate robust evidence Phase 2b and 3 studies intended to address key regulatory considerations for psychedelics 50 µg control dose in Panora
Slide 13: DT120's Clinical Activity Stands Out Compared to Approved GAD Therapies
Corporate Presentation | January 2026 DT120’s Clinical Activity Stands Out Compared to Approved GAD Therapies The information presented in this slide is derived from multiple clinical trials, each conducted under distinct protocols and settings. As such, these data may not be directly comparable due
Slide 14: Robust Phase 3 DT120 ODT Development Program Aiming for Broad Label
Robust Phase 3 DT120 ODT Development Program Aiming for Broad Label Corporate Presentation | January 2026 Studies employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) which allows f
Slide 15: Two Complementary Pivotal GAD Study Designs
Two Complementary Pivotal GAD Study Designs Corporate Presentation | January 2026 Studies will employ an adaptive design with interim blinded sample size re-estimation based on nuisance parameters (e.g. patient retention rate, variability of primary outcome measure) to attempt to maintain statistica
Slide 16: Two Complementary Pivotal MDD Study Designs
Two Complementary Pivotal MDD Study Designs Corporate Presentation | January 2026 Clinical study designs subject to ongoing regulatory discussion and review, including of Phase 3 clinical trial protocols. MADRS: Montgomery-Åsberg Depression Rating Scale; MDD: Major Depressive Disorder; ODT: orally d
Slide 17: Regulatory Elements Support DT120 ODT NDA Strategy
Corporate Presentation | January 2026 Regulatory Elements Support DT120 ODT NDA Strategy Study MMED008 internal study documents and calculations. Comparisons to standard of care/other drug classes based on historical comparison not head-to-head comparison trial. GAD: generalized anxiety disorder; ND
Slide 18: Commercial Framework: DT120 ODT Lysergide tartrate
Commercial Framework DT120 ODT Lysergide tartrate 02
Slide 19: Large, Identified, Accessible Opportunity for DT120 ODT
Corporate Presentation | January 2026 Large, Identified, Accessible Opportunity for DT120 ODT Bandelow B et al. World J Biol Psychiatry. 2008;9(4):248-312. 2. Ansara ED. Ment Health Clin. 2020;10(6):326-334. 3. Fagan HA, Baldwin DS. Expert Rev Neurother. 2023;23(6):535-548. 4. Garakani A et al. Fron
Slide 20: DT120 ODT dosing session and patient experience
Patients are supported by DSMs, healthcare professionals who passively observe and offer comfort care such as assistance with food or restrooms breaks. Psychotherapy is not offered or required but may be added outside a dosing session based on a decision between a provider and patient to support ind
Slide 21: Psychiatry is Primed for Strong Adoption of DT120 ODT
75% believe there is a significant unmet need in GAD1 Physicians Psychiatry is Primed for Strong Adoption of DT120 ODT Market research on file. GAD: generalized anxiety disorder; ODT: orally disintegrating tablet ; TPP: target product profile Motivated to prescribe 70% of surveyed HCPs intend to pre
Slide 22: Framing the Compelling Opportunity for DT120 ODT
Framing the Compelling Opportunity for DT120 ODT Corporate Presentation | January 2026 Potential Annual Revenue Opportunity per 100,000 patients Opportunity Drivers Calculations on file; Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings Report. RTI In
Slide 23: A Commercial Example: San Francisco
Corporate Presentation | January 2026 San Francisco metro area is approximately 1.4% of the US population with 49 top HCPs at 44 clinics that could potentially prescribe DT120 ODT San Francisco Metro Contribution (per 100k nationwide) 44 top target psychiatric clinics2 32 average patients treated pe
Slide 24: Program Update: DT402 R(-)-MDMA
Program Update DT402 R(-)-MDMA 03
Slide 25: DT402 Phase 2a Study in Autism Spectrum Disorder (ASD)
DT402 Phase 2a Study in Autism Spectrum Disorder (ASD) Corporate Presentation | January 2026 Shaw KA, Williams S, Patrick ME, et al. Prevalence and Early Identification of Autism Spectrum Disorder Among Children Aged 4 and 8 Years — Autism and Developmental Disabilities Monitoring Network, 16 Sites,
Slide 26: Program Update Summary
Program Update Summary 04
Slide 27: Value Creation Opportunity Shaped by Two Distinct Drivers
Corporate Presentation | January 2026 Value Creation Opportunity Shaped by Two Distinct Drivers1 Timing estimates subject to clinical progress and regulatory interactions. ASD: autism spectrum disorder; GAD: generalized anxiety disorder; TLR: Topline Data Readout Clinical & Regulatory Execution 2026
Slide 28: Financial Summary & Anticipated Milestones
Corporate Presentation | January 2026 Financial Summary & Anticipated Milestones Cash, cash equivalents and investments as of December 31, 2025 is ~$412 million. This preliminary unaudited financial information presented is an estimate based on information available to management as of the date of t
Slide 29: Definium Therapeutics
Definium THERAPEUTICS:
Mind Medicine (MindMed) — Investor Presentation (January 2026) on 6ix